Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Several studies have implicated the dopamine transporter gene (DAT1) as conferring susceptibility to attention deficit hyperactivity disorder (ADHD), in particular, a VNTR situated at the 3′ end of the gene. In addition, the 10‐repeat VNTR allele associated with ADHD has been reported to be associated with an over‐active transporter protein (DAT). Thus children possessing this variant might be particularly responsive to methylphenidate, a drug known to act by blocking DAT. We have examined this hypothesis and now report an association between the 10‐repeat VNTR DAT1 polymorphism and retrospectively rated methylphenidate response in a sample of 119 Irish children with ADHD (χ 2 = 7.918, df = 1, P = 0.005). Our findings suggest a role for the 10‐repeat DAT1 risk allele in medication response and may help to predict positive clinical outcome in ADHD. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conners, C. K., Sitarenios, G., Parker, J. D. A., & Epstein, J. N. (1998) · Journal of Abnormal Child Psychology · doi:10.1023/a:1022602400621 · Cited by 1,772
The Child and Adolescent Psychiatric Assessment (CAPA)
Angold, A., Prendergast, M., Cox, A., Harrington, R., Simonoff, E., & Rutter, M. (1995) · Psychological Medicine · doi:10.1017/s003329170003498x · Cited by 968
LEVY, F., HAY, D. A., McSTEPHEN, M., WOOD, C., & WALDMAN, I. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199706000-00009 · Cited by 956 · cited 2×
“The exact aetiology is unknown, but a strong genetic component has been demonstrated from the findings of family [Biederman et al., 1992; Faraone et al., 1994], twin [Levy et al., 1997], and adoption studies [Cadoret and Stewart, 1991].”
BackgroundSelf-citationPharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Self-citationBiederman, J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820090056010 · Cited by 771
Dopamine transporter density in patients with attention deficit hyperactivity disorder
Dougherty, D. D., Bonab, A. A., Spencer, T. J., Rauch, S. L., Madras, B. K., & Fischman, A. J. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04030-1 · Cited by 684 · cited 2×
“Three recent functional imaging studies demonstrate increased dopamine transporter density in ADHD [Dougherty et al., 1999; Dresel et al., 2000; Krause et al., 2000] and reduction in density on treatment with methylphenidate in two studies [Dresel et al., 2000; Krause et al., 2000].”
BackgroundGenotype Influences In Vivo Dopamine Transporter Availability in Human Striatum
Heinz, A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00099-8 · Cited by 538 · cited 1×
“Additional information can be found inKirley et al. [2002]. To confirm DSM-IV and/or ICD-10 diagnoses of ADHD, one or both parents of each child were interviewed using the Child and Adolescent Psychiatric Assessment (CAPA) [Angold and Costello, 2000].”
MethodKrause, K.-H., Dresel, S. H., Krause, J., Kung, H. F., & Tatsch, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01040-5 · Cited by 521 · cited 7×
“, 2000] and that administration of methylphenidate reduces transporter density to near normal levels in ADHD patients [Dresel et al., 2000; Krause et al., 2000].”
BackgroundInfluentialGill, M., Daly, G., Heron, S., Hawi, Z., & Fitzgerald, M. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000290 · Cited by 482
Self-citationMill, J., Asherson, P., Browes, C., D'Souza, U., & Craig, I. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.b.10948 · Cited by 341
Dresel, S., Krause, J., Krause, K.-H., LaFougere, C., Brinkbäumer, K., Kung, H. F., Hahn, K., & Tatsch, K. (2000) · European Journal of Nuclear Medicine · doi:10.1007/s002590000330 · Cited by 278 · cited 7×
“, 2000] and that administration of methylphenidate reduces transporter density to near normal levels in ADHD patients [Dresel et al., 2000; Krause et al., 2000].”
BackgroundInfluentialAnti-hyperactivity medication: methylphenidate and amphetamine
Seeman, P., & Madras, B. K. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000421 · Cited by 252
Santosh, P. J., & Taylor, E. (2000) · European Child & Adolescent Psychiatry · doi:10.1007/s007870070017 · Cited by 94
Cited by
The Dopamine Transporter and Attention-Deficit/Hyperactivity Disorder
Madras, B. K., Miller, G. M., & Fischman, A. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.011 · Cited by 393
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Brookes, K.-J., Mill, J., Guindalini, C., Curran, S., Xu, X., Knight, J., Chen, C.-K., Huang, Y.-S., Sethna, V., Taylor, E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.1.74 · Cited by 322
VanNess, S. H., Owens, M. J., & Kilts, C. D. (2005) · BMC Genetics · doi:10.1186/1471-2156-6-55 · Cited by 306
Attention-deficit-hyperactivity disorder and reward deficiency syndrome
Oscar Berman, M., Blum, K., Chen, T. J., Braverman, E., Waite, R., Downs, W., Arcuri, V., Notaro, A., Palomo, T., & Comings (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2627 · Cited by 248
“Although these interesting pharmacogenomic fi ndings have been confi rmed by some (Kirley et al 2003), they await further replication.”
Background
Metadata
- Authors
- Kirley, A., Lowe, N., Hawi, Z., Mullins, C., Daly, G., Waldman, I., McCarron, M., O'Donnell, D., Fitzgerald, M., & Gill, M.
- Venue
- American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Publisher
- Wiley
- Published
- 2003-06-09
- Volume
- 121B
- Issue
- 1
- Pages
- 50-54
- ISSN
- 1552-4841 (ISSN-L)
- 1552-485X
- OpenAlex
- W2231500275
- Cited by
- 151
- References
- 13
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.